A new partnership is aiming to accelerate the growth of UK health tech startups in the US market.
The arrangement will see Oxford Science Enterprises (OSE) and Cedars-Sinai Intellectual Property Company co-investing in health tech start-ups coming out of Oxford, a hotbed of life sciences and health innovation.
Cedars-Sinai Intellectual Property Company and OSE have initially invested US$2m in Neu Health, a spin-out from the University of Oxford.
It offers a digital smartphone-based neurology care platform to improve outcomes for Parkinson’s disease and dementia patients. This investment follows Neu Health’s participation in Cedars-Sinai’s 10th Accelerator programme last year.
Shlomo Melmed, dean of the Medical Faculty at Cedars-Sinai, says: “The research produced at Oxford is of the highest calibre.
“An ongoing relationship with Oxford Science Enterprises will serve our patients and also strengthen the academic and clinical missions of Cedars-Sinai.”
Heather Roxborough, senior partner of health tech at Oxford Science Enterprises, says: “We are excited to strengthen our relationship with Cedars-Sinai, a leading US health system, given our shared commitment to commercialising world-leading research and building innovative businesses.
“This partnership plays a critical role in accelerating US market entry for our companies by providing access to invaluable commercial and clinical insights and the opportunity to test our healthcare technologies live in the US market.”
The two organisations aim to help grow health tech start-ups, expand US and UK market reach and plan future potential alliances on both sides of the Atlantic.
